Skip to content
Buzza Start Learning
Learn with real videos

Bilingual YouTube Learning

▶
Choose a video to start learning Choose a video from the full Library to start learning.
Time English Language 2 Action
00:04
I've been writing about global health and medical innovation for years,
00:09
and when I tell my friends and family how much progress there's been,
00:13
the reaction is almost always the same.
00:16
They had no idea most of it was happening.
00:19
Take the most common cause of death today, heart disease.
00:23
People today have roughly a quarter the chance of dying from heart disease
00:27
as people did in the 1950s at the same age.
00:31
A quarter.
00:32
Back then, there were no statins, no cholesterol testing,
00:37
no implanted pacemakers,
00:39
no anti-smoking campaigns, no bans on trans fats,
00:43
no bypass surgery, no CPR.
00:47
But hardly anyone hears
00:48
about the long-term impact of those breakthroughs.
00:52
When progress happens gradually,
00:54
it's rarely considered news.
00:57
And I think it's a problem.
00:58
I think it’s part of why people don’t know how important it’s all been --
01:02
public health, vaccines and all the rest --
01:05
in improving people’s lives.
01:08
But what I want to tell you about
01:09
is the thing that doesn't make the news at all.
01:12
Not the breakthroughs themselves,
01:14
but everything that got in the way of them.
01:18
I used to have this impression that breakthroughs were uncommon,
01:21
sporadic,
01:22
sometimes happening by pure chance,
01:25
sometimes by sheer determination.
01:29
The way I see it now,
01:31
it's more like there's a continuous stream of medical innovation every year.
01:37
In just the last two years, for example,
01:40
we've had a new antiviral against HIV,
01:44
which protects against infections with an efficacy of nearly 100 percent
01:50
with just a single dose given every six months.
01:54
There are new drugs that reduce cholesterol levels by 60 percent,
01:57
beyond the effect of statins.
02:00
There are new treatments that slow down the progression of certain cancers,
02:04
certain lung cancers, brain cancer and multiple myeloma by half or more.
02:11
And in just the last five years,
02:13
we've had new vaccines against four diseases for the very first time.
02:18
COVID, of course,
02:19
but also the first malaria vaccine,
02:21
the first chikungunya vaccine and the first vaccine against RSV.
02:28
The tools to develop new drugs and vaccines have improved enormously.
02:32
Like genome sequencing, for example,
02:34
which has touched almost every part of biology.
02:38
Back when the Human Genome Project was completed in 2003,
02:42
it cost $50 million to sequence one person’s genome,
02:47
and it took half a year.
02:48
Now it takes under four hours
02:52
and it costs a few hundred dollars.
02:54
There's also been a revolution in the technology of microscopes.
02:58
Over the past 200 years,
03:01
their resolution has increased over 10,000-fold.
03:06
We can now see viruses down to their individual atoms
03:10
and design new drugs to target them extremely precisely.
03:14
This is RSV, respiratory syncytial virus.
03:18
It's in the middle right there.
03:19
And we can now see its atomic structure on the right.
03:23
Until the 1930s,
03:24
no one had ever seen a virus.
03:28
So if our technology has advanced so much,
03:33
why are so many diseases still untreatable today?
03:38
What I've learned is that technology isn't always the barrier.
03:43
Sometimes it’s about the funding, the institutions and the incentives.
03:48
We recently got a new malaria vaccine, as I mentioned,
03:51
and when I first heard about it, I was amazed.
03:54
I remember learning
03:56
that malaria was a very complicated disease, scientifically.
03:59
It's caused by a parasite, not a virus or bacterium.
04:02
And that parasite changes shape multiple times during its life cycle,
04:07
which makes it really hard to know what to target with a vaccine.
04:11
So I wanted to write about it, this amazing breakthrough.
04:15
But one of the first things I learned about this new malaria vaccine
04:18
that was introduced just a few years ago,
04:21
was that it was developed in the '90s.
04:24
Decades ago.
04:26
The researchers who developed it, struggled to find funding to test it
04:30
at every stage of the process.
04:33
There was no commercial incentive.
04:35
It's not profitable to develop new drugs
04:38
and vaccines against diseases
04:40
that affect people in poverty, in poorer countries,
04:43
even if millions of children might benefit.
04:46
Even if there’s a huge economic benefit as well.
04:50
It took foreign aid and philanthropy to fund the research to test it.
04:54
And it literally took decades to reach the children who needed it.
04:58
When I learned about this,
05:01
I felt like there was nothing to celebrate.
05:03
It seemed more like a failure.
05:06
How could we let that happen?
05:08
How could it take so long to test a vaccine
05:10
that had already been developed,
05:12
while half a million children were dying from malaria every year?
05:16
Why wasn't that the story?
05:20
Those children aren't coming back.
05:24
But what I wanted to know was how we could prevent that from happening again.
05:30
Like, what if we could change the economic incentives?
05:35
Well, economists have come up with an idea to do just that.
05:39
It’s called an “advanced market commitment.”
05:42
It's where donors commit to buying a vaccine at a certain price per dose,
05:46
but only if it's developed and proven safe and effective.
05:50
That commitment gives companies the confidence to invest in it
05:54
in the first place,
05:56
and it can bring vaccines into existence
05:58
that would otherwise never get made.
06:00
And most importantly,
06:01
it makes sure that they're manufactured at scale
06:04
and sold at an affordable price,
06:06
so they reach children who need them.
06:10
That idea was used over a decade ago
06:12
to help develop new vaccines against pneumococcal disease,
06:15
which is a deadly bacterial infection of the lungs.
06:19
Vaccines already existed,
06:21
but they didn't include the strains that were common in Africa and South Asia.
06:26
So in 2009, several countries and philanthropists came together
06:30
to fund an advanced market commitment for new vaccines.
06:34
And it actually worked.
06:35
Several companies developed them,
06:37
and they reached children much faster than usual.